Breaking News Instant updates and real-time market news.

2020-10-28 08:47:20 RARE Ultragenyx $97.50 / +6.36 (+6.98%) 08:47 10/28/20 10/28 08:47 10/28/20 08:47	Ultragenyx price target raised to $115 from $110 at SVB Leerink SVB Leerink analyst Joseph Schwartz raised the firm's price target on Ultragenyx to $115 from $110 and keeps an Outperform rating on the shares. The analyst notes that the company reported strong Q3 financial results and provided the Street with program updates. Based on Ultragenyx's commercial business that is steadily growing and a flurry of pipeline activities, Schwartz is increasingly optimistic that Ultragenyx may be able to approach its $1B sales goal by 2025.	09 Nov 29 Oct
RARE Ultragenyx $97.50 / +6.36 (+6.98%) 10/28/20 Truist Ultragenyx price target raised to $110 from $88 at Truist 10/28/20 Barclays Ultragenyx price target raised to $121 from $99 at Barclays 10/27/20 Piper Sandler Ultragenyx price target raised to $108 from $83 at Piper Sandler 10/23/20 Piper Sandler Ultragenyx deal with Solid Biosciences looks 'solid,' says Piper Sandler

2020-10-28 08:47:20

RARE

Ultragenyx

$97.50 / +6.36 (+6.98%)

08:47

10/28/20

10/28

08:47

10/28/20

08:47

Ultragenyx price target raised to $115 from $110 at SVB Leerink

SVB Leerink analyst Joseph Schwartz raised the firm's price target on Ultragenyx to $115 from $110 and keeps an Outperform rating on the shares. The analyst notes that the company reported strong Q3 financial results and provided the Street with program updates. Based on Ultragenyx's commercial business that is steadily growing and a flurry of pipeline activities, Schwartz is increasingly optimistic that Ultragenyx may be able to approach its $1B sales goal by 2025.

09
Nov

29
Oct

RARE Ultragenyx

$97.50 / +6.36 (+6.98%)

10/28/20 Truist: Ultragenyx price target raised to $110 from $88 at Truist

10/28/20 Barclays: Ultragenyx price target raised to $121 from $99 at Barclays

10/27/20 Piper Sandler: Ultragenyx price target raised to $108 from $83 at Piper Sandler

10/23/20 Piper Sandler: Ultragenyx deal with Solid Biosciences looks 'solid,' says Piper Sandler

TODAY'S FREE FLY STORIES

Recommendations	Societe Generale price target raised to EUR 16.80 from EUR 16.30 at Barclays » 15:07 01/22/21 01/22 15:07 01/22/21 15:07 SCGLY Societe Generale $0.00 / + (+0.00%) Barclays analyst Omar… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals SCGLY Societe Generale $0.00 / + (+0.00%) 01/08/21 Societe Generale increases shareholding in ArcelorMittal 12/07/20 Societe Generale to shut 600 French branches, cut EUR450M in costs by 2025 11/27/20 Societe Generale notifies ArcelorMittal of shareholding increase 11/02/20 Erytech Pharma secures EUR 10M in financing guaranteed by French government SCGLY Societe Generale $0.00 / + (+0.00%) 01/14/21 Morgan Stanley Societe Generale price target raised to EUR 18.30 from EUR 18 at Morgan Stanley 01/13/21 JPMorgan Societe Generale price target raised to EUR 23 from EUR 22 at JPMorgan 12/10/20 Morgan Stanley Societe Generale price target lowered to EUR 18 from EUR 19 at Morgan Stanley 12/09/20 UBS Societe Generale price target raised to EUR 18 from EUR 16.50 at UBS SCGLY Societe Generale $0.00 / + (+0.00%) 11/09/20 Societe Generale to cut 650 jobs in France, Reuters reports 11/08/20 Societe Generale planning to cut 650 jobs, Bloomberg says 10/30/20 Societe Generale seeks sale of Lyxor asset management unit, Bloomberg reports
Recommendations	Roche price target lowered to CHF 375 from CHF 395 at Barclays » 15:06 01/22/21 01/22 15:06 01/22/21 15:06 RHHBY Roche $0.00 / + (+0.00%) Barclays analyst Emmanuel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $0.00 / + (+0.00%) 01/21/21 Roche announces FDA acceptance of Genentech Esbriet sNDA 01/12/21 Roche confirms U.S to buy additional doses of Regeneron's Cov-19 cocktail 01/07/21 Roche granted FDA orphan drug status for Atezolizumab in esophageal cancer 01/06/21 Pluristem appoints Maital Shemesh-Rasmussen, Rami Levi to board RHHBY Roche $0.00 / + (+0.00%) 01/15/21 Deutsche Bank Roche initiated with a Hold at Deutsche Bank 01/12/21 UBS Roche price target lowered to CHF 355 from CHF 365 at UBS 01/11/21 Berenberg Roche price target lowered to CHF 325 from CHF 350 at Berenberg 01/11/21 Benchmark Phesgo EU approval/Horizon deal fuel Halozyme increased guidance, says Benchmark RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS RHHBY Roche $0.00 / + (+0.00%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says RHHBY Roche $0.00 / + (+0.00%) 12/26/20 Week in review: How Trump's policies moved stocks 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/21/20 Week in review: How Trump's policies moved stocks 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/04/21 Roche - RHHBY
Recommendations	ProsiebenSat price target raised to EUR 15 from EUR 12.50 at Barclays » 15:06 01/22/21 01/22 15:06 01/22/21 15:06 PBSFY ProsiebenSat $0.00 / + (+0.00%) Barclays analyst Julien… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research PBSFY ProsiebenSat $0.00 / + (+0.00%) 12:48 Today Citi ProsiebenSat price target raised to EUR 16.50 at Citi 12:41 Today JPMorgan ProsiebenSat price target raised to EUR 21 from EUR 19.50 at JPMorgan 01/21/21 Morgan Stanley ProsiebenSat price target raised to EUR 10 from EUR 7.50 at Morgan Stanley 01/20/21 BofA ProsiebenSat downgraded to Underperform from Neutral at BofA
Recommendations	Novartis price target raised to CHF 80 from CHF 75 at Barclays » 15:04 01/22/21 01/22 15:04 01/22/21 15:04 NVS Novartis $96.98 / +0.13 (+0.13%) Barclays analyst Emmanuel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events NVS Novartis $96.98 / +0.13 (+0.13%) 01/21/21 Novartis Gene Therapies gets FDA Orphan Drug Designation in Friedreich's Ataxia 01/12/21 Novartis reports pact to in-license tislelizumab outside China from BeiGene 12/19/20 Novartis receives complete response letter from U.S. FDA for inclisiran 12/17/20 Mesoblast's COVID remestemcel trial not likely to meet mortality reduction goal NVS Novartis $96.98 / +0.13 (+0.13%) 01/15/21 Deutsche Bank Novartis initiated with a Buy at Deutsche Bank 01/12/21 Piper Sandler BeiGene price target raised to $190 from $185 at Piper Sandler 01/08/21 Morgan Stanley Novartis price target raised to CHF 104 from CHF 102 at Morgan Stanley 01/08/21 Morgan Stanley Roche downgraded to Equal Weight from Overweight at Morgan Stanley NVS Novartis $96.98 / +0.13 (+0.13%) 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c) 10/27/20 Novartis raises FY20 core operating income growth outlook 10/27/20 Novartis reports Q3 core EPS $1.52, consensus $1.45 07/28/20 Fly Intel: What to watch in large-cap biotech earnings reports NVS Novartis $96.98 / +0.13 (+0.13%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 08/17/20 Novartis patent upheld on Gilenya multiple sclerosis drug, Bloomberg reports NVS Novartis $96.98 / +0.13 (+0.13%) 12/26/20 Week in review: How Trump's policies moved stocks 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/21/20 Week in review: How Trump's policies moved stocks 11/20/20 Fly Intel: Wall Street's top stories for Friday 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference
Recommendations	Natixis price target raised to EUR 3.70 from EUR 3.40 at Barclays » 15:04 01/22/21 01/22 15:04 01/22/21 15:04 NTXFF Natixis $0.00 / + (+0.00%) Barclays analyst Omar… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research NTXFF Natixis $0.00 / + (+0.00%) 01/21/21 Deutsche Bank Natixis price target raised to EUR 3.10 from EUR 3 at Deutsche Bank 01/14/21 Jefferies Natixis downgraded to Hold from Buy at Jefferies 11/13/20 Deutsche Bank Natixis price target raised to EUR 3 from EUR 2.80 at Deutsche Bank 09/01/20 Exane BNP Paribas Natixis upgraded to Neutral from Underperform at Exane BNP Paribas

Recommendations	Grifols price target lowered to EUR 31 from EUR 32 at Barclays » 15:03 01/22/21 01/22 15:03 01/22/21 15:03 GRFS Grifols $19.24 / -0.09 (-0.47%) Barclays analyst Emily… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly GRFS Grifols $19.24 / -0.09 (-0.47%) 01/18/21 Grifols to begin clinical trial in Spain for new COVID-19 drug 11/13/20 Soros takes stake in Palantir, exits TransDigm position 11/09/20 Grifols acquires remaining 49% of Goetech for $60.2M 10/09/20 Grifols begins anti-SARS-CoV-2 hyperimmune globulin trial GRFS Grifols $19.24 / -0.09 (-0.47%) 01/20/21 Credit Suisse Grifols price target lowered to EUR 26 from EUR 27 at Credit Suisse 01/13/21 Morgan Stanley Grifols price target lowered to EUR 31 from EUR 32 at Morgan Stanley 12/09/20 Morgan Stanley Grifols price target raised to EUR 32 from EUR 31 at Morgan Stanley 11/06/20 Morgan Stanley Grifols price target raised to EUR 31 from EUR 30 at Morgan Stanley GRFS Grifols $19.24 / -0.09 (-0.47%) 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports GRFS Grifols $19.24 / -0.09 (-0.47%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers
Recommendations	Carlsberg price target raised to DKK 1,178 from DKK 1,021 at Barclays » 15:01 01/22/21 01/22 15:01 01/22/21 15:01 CABGY Carlsberg $0.00 / + (+0.00%) Barclays analyst Laurence… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research CABGY Carlsberg $0.00 / + (+0.00%) 01/15/21 Berenberg Carlsberg price target lowered to DKK 1,086 from DKK 1,212 at Berenberg 01/15/21 Deutsche Bank Carlsberg price target lowered to DKK 1,150 from DKK 1,165 at Deutsche Bank 01/12/21 UBS Carlsberg price target raised to DKK 1,100 from DKK 1,030 at UBS 12/03/20 JPMorgan Carlsberg price target raised to DKK 1,215 from DKK 1,050 at JPMorgan
Recommendations	BNP Paribas price target raised to EUR 40.30 from EUR 39.20 at Barclays » 15:01 01/22/21 01/22 15:01 01/22/21 15:01 BNPQY BNP Paribas $0.00 / + (+0.00%) Barclays analyst Omar… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Periodicals Events BNPQY BNP Paribas $0.00 / + (+0.00%) 01/14/21 Morgan Stanley BNP Paribas price target raised to EUR 57 from EUR 53 at Morgan Stanley 01/13/21 JPMorgan BNP Paribas price target raised to EUR 53 from EUR 51 at JPMorgan 01/11/21 Deutsche Bank BNP Paribas price target raised to EUR 52 from EUR 48 at Deutsche Bank 01/07/21 UBS BNP Paribas price target raised to EUR 50 from EUR 48 at UBS BNPQY BNP Paribas $0.00 / + (+0.00%) 12/02/20 Engie gathers advisers for $6B services disposal, Bloomberg reports 02/05/21 BNP Paribas - BNPQY
Recommendations	AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays » 15:00 01/22/21 01/22 15:00 01/22/21 15:00 AZN AstraZeneca $53.30 / +0.77 (+1.47%) Barclays analyst Emmanuel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $53.30 / +0.77 (+1.47%) 01/20/21 AstraZeneca's Enhertu approved in EU for HER2-positive metastatic breast cancer 01/18/21 AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC AZN AstraZeneca $53.30 / +0.77 (+1.47%) 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank AZN AstraZeneca $53.30 / +0.77 (+1.47%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AZN AstraZeneca $53.30 / +0.77 (+1.47%) 11:53 Today EU to see delay of AstraZeneca COVID vaccine delivery, FT reports 10:38 Today AstraZeneca informs EU Commission of vaccine delivery issues, Bild says 01/17/21 Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says 01/15/21 AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports AZN AstraZeneca $53.30 / +0.77 (+1.47%) 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/20/21 PDUFA Date for Tagrisso (Osimertinib) 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN AstraZeneca $53.30 / +0.77 (+1.47%) 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish
Earnings	Gamco Investors sees Q4 EPS 69c-73c vs. 91c last year » 14:53 01/22/21 01/22 14:53 01/22/21 14:53 GBL Gamco Investors $17.37 / +0.02 (+0.12%) Gamco Investors announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings GBL Gamco Investors $17.37 / +0.02 (+0.12%) 11/23/20 Gamco Investors declares special 90c per share dividend GBL Gamco Investors $17.37 / +0.02 (+0.12%) 10/16/20 Gamco Investors sees Q3 EPS 59c-63c vs. 50c last year

Hot Stocks	Curaleaf announces launch of adult-use operations in Arizona » 14:50 01/22/21 01/22 14:50 01/22/21 14:50 CURLF Curaleaf $0.00 / + (+0.00%) Curaleaf Holdings… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly CURLF Curaleaf $0.00 / + (+0.00%) 11/17/20 Curaleaf names Joseph Bayern as CEO, effective January 1, 2021 11/06/20 Curaleaf announces asset divestitures in Maryland to TerrAscend for $31.5M 10/08/20 Curaleaf receives approval for acquisition of Alternative Therapies Group 08/31/20 Curaleaf announces first retail location in Utah market CURLF Curaleaf $0.00 / + (+0.00%) 01/20/21 Roth Capital Curaleaf price target raised to $20 from $14 at Roth Capital 01/19/21 Needham Curaleaf price target raised to $18.50 from $14 at Needham 01/13/21 Canaccord Curaleaf price target raised to C$23.50 from C$18.50 at Canaccord 01/11/21 Roth Capital Curaleaf credit facility completed on favorable terms, says Roth Capital CURLF Curaleaf $0.00 / + (+0.00%) 11/17/20 Curaleaf reports Q3 EPS (1c) vs. (1c) a year ago 08/18/20 Curaleaf sees 'continued rise' in managed revenue, adjusted EBITDA 08/18/20 Curaleaf Holdings reported Q2 EPS 0c vs. (5c) last year CURLF Curaleaf $0.00 / + (+0.00%) 11/05/20 Governor Cuomo says NY 'ripe' for pot legalization, amNewYork says CURLF Curaleaf $0.00 / + (+0.00%) 11/28/20 Week in review: How Trump's policies moved stocks
Periodicals	Comcast to shut down sports network NBCSN by end of year, WSJ reports » 14:48 01/22/21 01/22 14:48 01/22/21 14:48 CMCSA Comcast $48.75 / -0.37 (-0.75%) Comcast's… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CMCSA Comcast $48.75 / -0.37 (-0.75%) 01/19/21 Netflix says past year 'testament' to company's approach 01/07/21 Comscore announces strategic investment by Charter, Qurate Retail, Cerberus 01/07/21 NBCUniversal, Charter announce multi-year distribution agreement 01/07/21 Tegna, FreeWheel announce new multi-year deal CMCSA Comcast $48.75 / -0.37 (-0.75%) 01/19/21 Barclays Comcast price target raised to $53 from $48 at Barclays 01/14/21 Macquarie Comcast price target raised to $58 from $53 at Macquarie 12/16/20 Morgan Stanley Morgan Stanley names Comcast a top pick, raises price target to $62 11/25/20 TD Securities Comcast downgraded to Hold after recent rally at TD Securities CMCSA Comcast $48.75 / -0.37 (-0.75%) 10/29/20 Comcast reports Q3 adj. EPS 65c, consensus 52c 10/28/20 Notable companies reporting before tomorrow's open 10/28/20 Notable companies reporting before tomorrow's open 07/30/20 Comcast reports Q2 adjusted EPS 69c, consensus 55c CMCSA Comcast $48.75 / -0.37 (-0.75%) 01/21/21 Japan expects Tokyo Olympics will have to be cancelled, The Times says 01/13/21 Amazon plans bid for Italy's 'top soccer TV rights,' Bloomberg says 12/19/20 Comcast well positioned for post-COVID world, Barron's says 12/10/20 Disney, NBCUniversal unlikely to follow WarnerMedia's 2021 media plan, CNBC says CMCSA Comcast $48.75 / -0.37 (-0.75%) 01/19/21 Fly Intel: What to watch in Netflix earnings report 12/10/20 Fly Intel: Wall Street's top stories for Thursday 11/25/20 Ford, Gap downgrades among today's top calls on Wall Street 11/03/20 Fly Intel: Wall Street's top stories for Tuesday 01/28/21 Comcast - CMCSA CMCSA Comcast $48.75 / -0.37 (-0.75%) 01/11/21 Comcast put volume heavy and directionally bearish 12/24/20 Unusual call flow in option market yesterday 12/23/20 $2M block of Comcast calls tied to hedge possible stock replacement trade 12/22/20 Unusually active option classes on open December 22nd
Options	Vuzix call volume above normal and directionally bullish » 14:45 01/22/21 01/22 14:45 01/22/21 14:45 VUZI Vuzix $11.57 / +0.685 (+6.29%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Options VUZI Vuzix $11.57 / +0.685 (+6.29%) 14:14 Today Vuzix says smart glasses used for worksite inspection via drone 12:53 Today Vuzix trading resumes 12:48 Today Vuzix trading halted, volatility trading pause 01/11/21 Vuzix confirms joint manufacturing and supply agreement with Jade Bird VUZI Vuzix $11.57 / +0.685 (+6.29%) 01/19/21 Maxim Vuzix price target raised to $13 from $6.50 at Maxim 09/04/20 Craig-Hallum Vuzix price target raised to $8 from $6 at Craig-Hallum 05/11/20 Alliance Global Partners Vuzix downgraded to Neutral from Buy at Alliance Global Partners VUZI Vuzix $11.57 / +0.685 (+6.29%) 01/15/21 Vuzix reports preliminary Q4 revenue $4M, consensus $3.52M 11/09/20 Vuzix reports Q3 EPS (13c), consensus (12c) 08/10/20 Vuzix reports Q2 EPS (13c), consensus (15c) VUZI Vuzix $11.57 / +0.685 (+6.29%) 12/18/20 Citron says 'no way' would be shorting Vuzix VUZI Vuzix $11.57 / +0.685 (+6.29%) 01/19/21 Largest borrow rate increases among liquid names 01/13/21 Vuzix call volume above normal and directionally bullish 12/22/20 Vuzix call volume above normal and directionally bullish 12/18/20 Vuzix call volume above normal and directionally bullish
General news	Treasury Action: consolidation rules the day heading into the weekend » 14:35 01/22/21 01/22 14:35 01/22/21 14:35 Treasury Action:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Options	Hilton put volume heavy and directionally bearish » 14:35 01/22/21 01/22 14:35 01/22/21 14:35 HLT Hilton $104.78 / -4 (-3.68%) Bearish flow noted in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options HLT Hilton $104.78 / -4 (-3.68%) 11/19/20 Pershing Square sees 'enormous snapback' in consumer travel post-vaccine 11/19/20 Pershing Square expects Hilton to emerge much stronger from Covid crisis 11/16/20 Hilton announces launch of $1B senior notes offering 11/16/20 Hilton announces launch of $1B senior notes offering HLT Hilton $104.78 / -4 (-3.68%) 01/12/21 Raymond James Hilton price target raised to $125 from $105 at Raymond James 01/05/21 Gordon Haskett Hilton price target raised to $114 from $97 at Gordon Haskett 12/15/20 Citi Hilton upgraded to Buy from Neutral at Citi 12/10/20 BTIG Airbnb initiated with a Neutral at BTIG HLT Hilton $104.78 / -4 (-3.68%) 11/04/20 Hilton reports Q3 adjusted EPS 6c, consensus (2c) 11/03/20 Notable companies reporting before tomorrow's open 11/03/20 Notable companies reporting before tomorrow's open 08/06/20 Hilton reports Q2 adjusted EPS (61c), consensus (31c) HLT Hilton $104.78 / -4 (-3.68%) 09/03/20 Hilton Times Square set to shutter, 200 jobs to be cut, WSJ reports HLT Hilton $104.78 / -4 (-3.68%) 12/15/20 Wells Fargo upgrade, Dick's Sporting initiation among top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street 11/04/20 Fly Intel: Pre-market Movers 08/14/20 Dual Tesla upgrades among today's top calls on Wall Street 02/17/21 Hilton - HLT HLT Hilton $104.78 / -4 (-3.68%) 10/28/20 Hilton put volume heavy and directionally bearish 10/22/20 Hilton call volume above normal and directionally bullish 10/21/20 Hilton call volume above normal and directionally bullish 09/21/20 Hilton put volume heavy and directionally bearish

Hot Stocks	GameStop extends rally as Citron stops commenting after 'mob' attack » 14:30 01/22/21 01/22 14:30 01/22/21 14:30 GME GameStop $58.29 / +15.31 (+35.62%) Shares of GameStop (GME)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options GME GameStop $58.29 / +15.31 (+35.62%) 12:48 Today GameStop trading resumes after volatility halt, shares up 52% to $65.56 12:46 Today GameStop trading resumes 12:41 Today GameStop trading halted, volatility trading pause 12:00 Today GameStop rises 19.2% GME GameStop $58.29 / +15.31 (+35.62%) 01/13/21 Standpoint Research GameStop downgraded to Hold from Buy at Standpoint Research 01/11/21 Benchmark Benchmark 'not surprised' by GameStop board change after 'disappointing' holiday 12/09/20 Benchmark GameStop price target lowered to $5 from $6 at Benchmark 12/04/20 Wedbush GameStop price target raised to $16 from $8 at Wedbush GME GameStop $58.29 / +15.31 (+35.62%) 12/08/20 GameStop reports Q3 adj. EPS (53c), consensus (85c) 12/08/20 GameStop reports Q3 EPS (29c), consensus (85c) 12/08/20 Notable companies reporting after market close 09/09/20 GameStop reports Q2 adj. EPS ($1.40), consensus ($1.13) GME GameStop $58.29 / +15.31 (+35.62%) 11:19 Today Citron Research no longer commenting on GameStop 01/19/21 Citron sees five reasons GameStop will trade 'back to $20 fast' 01/16/21 GameStop stock double last week, challenges remain, Barron's says 01/09/21 GameStop caught in vicious cycle, Barron's says GME GameStop $58.29 / +15.31 (+35.62%) 01/19/21 Game On: An exclusive talk with The Game Bakers' Emeric Thoa 01/12/21 Game On: Roblox files for direct listing as GameStop adds new directors 01/05/21 Game On: Nintendo buys 'Luigi's Mansion 3' developer Next Level Games 12/22/20 Game On: Sony pulls buggy 'Cyberpunk 2077' from PS Store GME GameStop $58.29 / +15.31 (+35.62%) 01/19/21 Largest borrow rate increases among liquid names 01/14/21 Notable open interest changes for January 14th 01/13/21 GameStop call volume above normal and directionally bullish 01/13/21 Largest borrow rate increases among liquid names
Hot Stocks	Eisman says 'regulatory story' Credit Acceptance is biggest short » 14:29 01/22/21 01/22 14:29 01/22/21 14:29 CACC Credit Acceptance $338.24 / -7.62 (-2.20%) Neuberger Berman Group… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CACC Credit Acceptance $338.24 / -7.62 (-2.20%) 08/31/20 Massachusetts AG sues Credit Acceptance over practices in auto loan business CACC Credit Acceptance $338.24 / -7.62 (-2.20%) 09/04/20 Stephens Stephens doesn't see quick settlement for Credit Acceptance given countersuit 08/31/20 Stephens MA lawsuit against Credit Acceptance not materially new, says Stephens 07/31/20 Janney Montgomery Scott Janney upgrades Credit Acceptance to Neutral on Q2 rebound 07/31/20 Janney Montgomery Scott Credit Acceptance upgraded to Neutral from Sell at Janney Montgomery Scott CACC Credit Acceptance $338.24 / -7.62 (-2.20%) 10/29/20 Credit Acceptance reports Q3 adj. EPS $9.36, consensus $5.69 07/30/20 Credit Acceptance reports Q2 EPS $8.63, consensus $4.84 CACC Credit Acceptance $338.24 / -7.62 (-2.20%) 08/31/20 Fly Intel: Wall Street's top stories for Monday
Periodicals	Mediaset lodges appeal against Vivendi stake court ruling, Reuters says » 14:27 01/22/21 01/22 14:27 01/22/21 14:27 MDIUY Mediaset $0.00 / + (+0.00%) , VIVHY Vivendi $0.00 / + (+0.00%) Mediaset (MDIUY) has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals VIVHY VIVHY Vivendi $0.00 / + (+0.00%) 12/30/20 LiveXLive Media appoints Maria Garrido to board of directors 12/18/20 Tencent Music consortium exercises option to acquire additional 10% of UMG MDIUY VIVHY MDIUY Mediaset $0.00 / + (+0.00%) 11/13/20 Berenberg Mediaset price target raised to EUR 1.90 from EUR 1.75 at Berenberg 11/12/20 Barclays Mediaset price target raised to EUR 2 from EUR 1.90 at Barclays 11/12/20 UBS Mediaset price target raised to EUR 2.05 from EUR 1.95 at UBS 09/10/20 UBS Mediaset price target raised to EUR 1.95 from EUR 1.80 at UBS VIVHY Vivendi $0.00 / + (+0.00%) 01/14/21 Barclays Vivendi price target raised to EUR 28.50 from EUR 27 at Barclays 01/12/21 UBS Vivendi price target raised to EUR 36 from EUR 33 at UBS 01/12/21 JPMorgan Vivendi price target raised to EUR 42 from EUR 38 at JPMorgan 01/11/21 Morgan Stanley Vivendi price target raised to EUR 36 from EUR 34 at Morgan Stanley VIVHY VIVHY Vivendi $0.00 / + (+0.00%) 10/28/20 Fly Intel: What to watch in Spotify earnings report 07/28/20 Fly Intel: What to watch in Spotify earnings report VIVHY VIVHY Vivendi $0.00 / + (+0.00%) 07/31/20 Facebook set to seal deals to show music videos, Bloomberg reports
Initiation	Huron initiated with a Buy at Sidoti » 14:27 01/22/21 01/22 14:27 01/22/21 14:27 HURN Huron $55.60 / -0.605 (-1.08%) Sidoti analyst Josh Vogel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly HURN Huron $55.60 / -0.605 (-1.08%) 01/07/21 Huron to acquire Unico Solution, terms undisclosed 11/02/20 Huron says restructuring plan to result in 145 job cuts 10/15/20 Huron announces acquisition of ForceIQ, terms undisclosed HURN Huron $55.60 / -0.605 (-1.08%) 12/18/20 Benchmark Huron upgraded to Buy at Benchmark on confidence in recovery 12/18/20 Benchmark Huron upgraded to Buy from Hold at Benchmark 11/04/20 Truist Huron price target lowered to $62 from $68 at Truist 05/01/20 Benchmark Huron downgraded to Hold on limited visibility at Benchmark HURN Huron $55.60 / -0.605 (-1.08%) 11/02/20 Huron raises FY20 EPS view to $1.95-$2.15 from $1.50-$1.80 11/02/20 Huron reports Q3 adjusted EPS 59c, consensus 27c 07/30/20 Huron sees FY20 EPS $1.50-$1.80, consensus $1.26 07/30/20 Huron reports Q2 EPS 68c, consensus 18c HURN Huron $55.60 / -0.605 (-1.08%) 07/30/20 Fly Intel: After-Hours Movers
Options	Kodak call volume above normal and directionally bullish » 14:25 01/22/21 01/22 14:25 01/22/21 14:25 KODK Eastman Kodak $9.48 / +0.28 (+3.04%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Periodicals On The Fly Options KODK Eastman Kodak $9.48 / +0.28 (+3.04%) 01/20/21 Eastman Kodak rises over 7% after Pigment.inc RDTG distribution deal 12/07/20 Eastman Kodak rises 56.2% 12/07/20 Eastman Kodak rises 83.3% 12/07/20 Eastman Kodak rises 76.2% KODK Eastman Kodak $9.48 / +0.28 (+3.04%) 11/10/20 Eastman Kodak report Q3 net loss ($445M) vs. ($5M) last year 08/11/20 Eastman Kodak reports Q2 operational EBITDA ($7M) vs. ($1M) last year KODK Eastman Kodak $9.48 / +0.28 (+3.04%) 12/07/20 Watchdog finds no wrongdoing in Kodak deal, WSJ reports 11/11/20 Former Kodak execs sold stock options they did not own, WSJ reports 10/19/20 Kodak will still work on making drug ingredients, CEO says at WSJ Tech Live 09/17/20 House Democrats questions findings of Kodak internal review, CNBC reports KODK Eastman Kodak $9.48 / +0.28 (+3.04%) 12/07/20 Fly Intel: Wall Street's top stories for Monday 12/07/20 Fly Intel: Wall Street's top stories at midday 12/07/20 Fly Intel: Pre-market Movers 11/10/20 Fly Intel: After-Hours Movers KODK Eastman Kodak $9.48 / +0.28 (+3.04%) 01/19/21 Kodak call volume above normal and directionally bullish 01/14/21 Heavy trading in Kodak calls and shares as stock lifts 7% 12/29/20 Kodak call volume above normal and directionally bullish 12/17/20 Kodak call volume above normal and directionally bullish

General news	Action Economics Survey results » 14:20 01/22/21 01/22 14:20 01/22/21 14:20 Action Economics Survey… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Technical Analysis	NASDAQ market internals summary » 14:17 01/22/21 01/22 14:17 01/22/21 14:17 $NSD NASDAQ Market Internals $0.00 / + (+0.00%) Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NSD NASDAQ Market Internals $0.00 / + (+0.00%) 13:17 Today NASDAQ market internals summary 12:17 Today NASDAQ market internals summary 11:17 Today NASDAQ market internals summary 10:17 Today NASDAQ market internals summary
Technical Analysis	NYSE market internals summary » 14:16 01/22/21 01/22 14:16 01/22/21 14:16 $NYE NYSE Market Internals $0.00 / + (+0.00%) Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Technical Analysis $NYE NYSE Market Internals $0.00 / + (+0.00%) 13:16 Today NYSE market internals summary 12:16 Today NYSE market internals summary 11:16 Today NYSE market internals summary 10:16 Today NYSE market internals summary
Hot Stocks	Vuzix says smart glasses used for worksite inspection via drone » 14:14 01/22/21 01/22 14:14 01/22/21 14:14 VUZI Vuzix $11.70 / +0.815 (+7.49%) Vuzix announced that the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Options VUZI Vuzix $11.70 / +0.815 (+7.49%) 12:53 Today Vuzix trading resumes 12:48 Today Vuzix trading halted, volatility trading pause 01/11/21 Vuzix confirms joint manufacturing and supply agreement with Jade Bird 12/29/20 Vuzix receives follow-on M400 Smart Glasses order VUZI Vuzix $11.70 / +0.815 (+7.49%) 01/19/21 Maxim Vuzix price target raised to $13 from $6.50 at Maxim 09/04/20 Craig-Hallum Vuzix price target raised to $8 from $6 at Craig-Hallum 05/11/20 Alliance Global Partners Vuzix downgraded to Neutral from Buy at Alliance Global Partners VUZI Vuzix $11.70 / +0.815 (+7.49%) 01/15/21 Vuzix reports preliminary Q4 revenue $4M, consensus $3.52M 11/09/20 Vuzix reports Q3 EPS (13c), consensus (12c) 08/10/20 Vuzix reports Q2 EPS (13c), consensus (15c) VUZI Vuzix $11.70 / +0.815 (+7.49%) 12/18/20 Citron says 'no way' would be shorting Vuzix VUZI Vuzix $11.70 / +0.815 (+7.49%) 01/19/21 Largest borrow rate increases among liquid names 01/13/21 Vuzix call volume above normal and directionally bullish 12/22/20 Vuzix call volume above normal and directionally bullish 12/18/20 Vuzix call volume above normal and directionally bullish
Initiation	Rakuten initiated with a Neutral at Goldman Sachs » 14:07 01/22/21 01/22 14:07 01/22/21 14:07 RKUNY Rakuten $0.00 / + (+0.00%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial

Events

Earnings calls, analyst events, roadshows and more

Tomorrow at 00:00

2021 VESS Annual Winter Meeting Conferences

Virtual Meeting
PFE
2021-01-24 at 00:00

PDUFA Date for Xalkori (Crizotinib) - January 2021 Government Event
2021-01-24 at 00:00

2021 VESS Annual Winter Meeting Conferences

Virtual Meeting
2021-01-25 at 00:00

Annual Virtual Washington DC Energy & Power Policy Field Trip Conferences

Virtual Field Trip
USB
2021-01-25 at 00:00

U.S. Bancorp Firm Sponsored Meetings

Virtual Meeting
SEEL
2021-01-25 at 00:00

Seelos Therapeutics Firm Sponsored Meetings

Virtual Meeting
FDX
2021-01-25 at 00:00

FedEx Firm Sponsored Meetings

Virtual Meeting
NAVB
2021-01-25 at 00:00

Navidea Firm Sponsored Meetings

Virtual Meeting
NBAC
2021-01-25 at 00:00

Newborn Acquisition Corp. Firm Sponsored Meetings

Virtual Meeting
2021-01-25 at 00:00

MacroStrategy Industry Meetings

Virtual Meeting

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley Priced at: $25.50 700K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital Priced at: $30.50 4.59M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright Priced at: $17.50 5.484M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald Priced at: $1.90 14.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright Priced at: $2.40 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim Priced at: $6.00 33.333M Shares DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse Priced at: $11.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel Priced at: $22.00 15.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE Priced at: $11.50 4.99M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler Priced at: $14.00 5.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush Priced at: $13.00 9.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen Priced at: $26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities Priced at: $22.50 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright Priced at: $91.00 1.923M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading Priced at: $8.50 11.765M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler Priced at: $7.00 14.286M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel Priced at: $28.00 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse Priced at: $66.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink Priced at: $24.75 4.85M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS Priced at: $66.00 3.788M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INO X INO Inovio Spot Secondary Managers: BofA, Jefferies & Cantor Fitzgerald, Oppenheimer Priced at: $8.50 2.655M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ONCS X ONCS OncoSec Spot Secondary Managers: BTIG Priced at: $5.45 7.71M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.30 7.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	VRAY X VRAY ViewRay Block Trade Managers: Morgan Stanley Priced at: $4.75 11.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP Priced at: $17.00 30.099M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance Priced at: $12.00 116.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies Priced at: $40.00 20M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen & Stifel, Wedbush, Academy Securities Priced at: $35.00 7.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DCBO X DCBO Docebo Secondary Managers: Morgan Stanley, Goldman Sachs & Canaccord Priced at: $49.67 2.013M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NVTA X NVTA Invitae Secondary Managers: JPMorgan, Morgan Stanley, Cowen & SVB Leerink Priced at: $51.50 7.77M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan Priced at: $22.00 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SI X SI Silvergate Capital Secondary Managers: Goldman Sachs, Keefe Bruyette & Canaccord, Compass Point, Craig-Hallum Priced at: $63.00 3.968M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACB X ACB Aurora Cannabis Spot Secondary Managers: BMO Capital, ATB Capital Markets Priced at: $10.45 12M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GSL X GSL Global Ship Lease Spot Secondary Managers: Jefferies & B. Riley Securities Priced at: $13.00 5.384M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PGEN X PGEN Precigen Spot Secondary Managers: Wells Fargo & Stifel, JMP Securities, H.C. Wainwright Priced at: $7.50 15M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SENS X SENS Senseonics Spot Secondary Managers: H.C. Wainwright Priced at: $1.925 51.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Ultragenyx price target raised to $115 from $110 at SVB Leerink

TODAY'S FREE FLY STORIES

Get Full Fly Access